Literature DB >> 19355

Correlation between oral toxicity and in vitro stability of Clostridium botulinum type A and B toxins of different molecular sizes.

S Sugii, I Ohishi, G Sakaguchi.   

Abstract

The in vitro sensitivity to acid and pepsin differed markedly among Clostridium botulinum type A and B toxins of different molecular sizes. The larger the molecular size of the toxin, the higher the resistance to these agents. Tye B derivative toxin was rapidly inactivated, but the progenitor toxins resisted in vitro exposure to rat intestinal juice. The molecular dissociation of the progenitor toxins did not occur in rat intestinal juice of pH 7.0, but did occur in a buffer solution of the same pH. The oral toxicity may depend mostly on the stability of toxin molecules in the stomach and, to a less extent, in the intestine. The present results seem to justify the conclusion that C. botulinum type A and B progenitor toxins with molecular sizes larger than 16S are more potent oral toxins than 12S progenitor toxins.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 19355      PMCID: PMC421049          DOI: 10.1128/iai.16.3.910-914.1977

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  14 in total

1.  Proceedings: Clostridium botulinum type A, B, E and F 12S toxins.

Authors:  S Kozaki; S Sugii; I Oishi; S Sakaguchi; G Sakaguchi
Journal:  Jpn J Med Sci Biol       Date:  1975-02

2.  Studies on immunity to toxins of Clostridium botulinum. I. A simplified procedure for isolation of type A toxin.

Authors:  J T DUFF; G G WRIGHT; J KLERER; D E MOORE; R H BIBLER
Journal:  J Bacteriol       Date:  1957-01       Impact factor: 3.490

3.  Botulinum type A toxin: properties of a toxic dissociation product.

Authors:  J WAGMAN; J B BATEMAN
Journal:  Arch Biochem Biophys       Date:  1953-08       Impact factor: 4.013

4.  ACTIVITY OF TYPE A BOTULINAL TOXIN AND HEMAGGLUTININ EXPOSED TO PROTEOLYTIC ENZYME.

Authors:  E A Meyer; C Lamanna
Journal:  J Bacteriol       Date:  1959-08       Impact factor: 3.490

5.  Studies on the oral toxicity of Clostridium botulinum toxin, type A.

Authors:  I W COLEMAN
Journal:  Can J Biochem Physiol       Date:  1954-01

6.  The action of proteolytic enzymes on Clostridium botulinum type A toxin.

Authors:  G HALLIWELL
Journal:  Biochem J       Date:  1954-09       Impact factor: 3.857

7.  Molecular construction of Clostridium botulinum type F progenitor toxin.

Authors:  I Ohishi; G Sakaguchi
Journal:  Appl Microbiol       Date:  1975-04

8.  Toxicity of purified botulinal toxin fed to mice.

Authors:  H Sugiyama; B R DasGupta; K H Yang
Journal:  Proc Soc Exp Biol Med       Date:  1974-11

9.  Purification and some properties of progenitor toxins of Clostridium botulinum type B.

Authors:  S Kozaki; S Sakaguchi; G Sakaguchi
Journal:  Infect Immun       Date:  1974-10       Impact factor: 3.441

10.  Oral toxicities of Clostridium botulinum toxins in response to molecular size.

Authors:  I Ohishi; S Sugii; G Sakaguchi
Journal:  Infect Immun       Date:  1977-04       Impact factor: 3.441

View more
  30 in total

1.  Purification of fully activated Clostridium botulinum serotype B toxin for treatment of patients with dystonia.

Authors:  Hideyuki Arimitsu; Kaoru Inoue; Yoshihiko Sakaguchi; Jaechul Lee; Yukako Fujinaga; Toshihiro Watanabe; Tohru Ohyama; Robert Hirst; Keiji Oguma
Journal:  Infect Immun       Date:  2003-03       Impact factor: 3.441

2.  The botulinum toxin complex meets E-cadherin on the way to its destination.

Authors:  Yo Sugawara; Yukako Fujinaga
Journal:  Cell Adh Migr       Date:  2011-01-01       Impact factor: 3.405

3.  Mass Spectrometric Identification and Differentiation of Botulinum Neurotoxins through Toxin Proteomics.

Authors:  Suzanne R Kalb; John R Barr
Journal:  Rev Anal Chem       Date:  2013-08       Impact factor: 3.067

4.  Clostridium botulinum types A, B, C1, and E produce proteins with or without hemagglutinating activity: do they share common amino acid sequences and genes?

Authors:  E Somers; B R DasGupta
Journal:  J Protein Chem       Date:  1991-08

Review 5.  Properties and use of botulinum toxin and other microbial neurotoxins in medicine.

Authors:  E J Schantz; E A Johnson
Journal:  Microbiol Rev       Date:  1992-03

6.  Pure botulinum neurotoxin is absorbed from the stomach and small intestine and produces peripheral neuromuscular blockade.

Authors:  A B Maksymowych; M Reinhard; C J Malizio; M C Goodnough; E A Johnson; L L Simpson
Journal:  Infect Immun       Date:  1999-09       Impact factor: 3.441

7.  Intestinal absorption of botulinum toxins of different molecular sizes in rats.

Authors:  S Sugii; I Ohishi; G Sakaguchi
Journal:  Infect Immun       Date:  1977-09       Impact factor: 3.441

8.  Biophysical characterization of the stability of the 150-kilodalton botulinum toxin, the nontoxic component, and the 900-kilodalton botulinum toxin complex species.

Authors:  F Chen; G M Kuziemko; R C Stevens
Journal:  Infect Immun       Date:  1998-06       Impact factor: 3.441

9.  Antibody mapping to domains of botulinum neurotoxin serotype A in the complexed and uncomplexed forms.

Authors:  F Chen; G M Kuziemko; P Amersdorfer; C Wong; J D Marks; R C Stevens
Journal:  Infect Immun       Date:  1997-05       Impact factor: 3.441

10.  Characterization of new formalin-detoxified botulinum neurotoxin toxoids.

Authors:  James E Keller
Journal:  Clin Vaccine Immunol       Date:  2008-07-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.